Preclinical drug screening in new generation Alzheimer’s disease mouse models: The MODEL-AD Consortium Strategy

Poster   Nov 24, 2017

 
Preclinical drug screening in new generation Alzheimer’s disease mouse models: The MODEL-AD Consortium Strategy
 
View Poster

P.R. Territo1, S.J. Sukoff Rizzo2, K. Onos2, J.A. Meyer1, J. Peters1, S.C. Persohn1, B.R. McCarthy1, A.A. Riley1, S. Quinney1, D. Jones1, M. Sasner2, G. Howell2, H. Williams2, A.J. Oblak1, B.L. Lamb1 and the MODEL-AD consortium

 
 

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License

 
View Poster
 
 
 

OTHER POSTERS

Chronic administration of a new therapeutic agent improves memory in a mouse model of Alzheimer’s disease with tau deposition.

Poster

Abnormal tau hyperphosphorylation and accumulation into neuronal neurofibrillary tangles are linked to neurodegeneration in Alzheimer’s disease. The aim of this study was to test the effects of a new therapeutic agent in a mouse model of tau deposition (Tg4510 mice). Mice treated with test agent-1 showed improvements in learning and memory compared to the control mice together with a reduction in tau oligomers in hippocampi homogenates.

READ MORE

Age-related Histological Changes in Subjects with Nasal Polyps and Healthy Controls

Poster

Significant histological differences in subjects with NP and healthy controls exist among different age groups.

READ MORE

Electrophysiological Changes Underlying Lapses in Memory Consolidation

Poster

In this study we explore the electrophysiological changes associated with lapses in memory consolidation.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery Neuroscience

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE